Immunome Inc (IMNM) returns
Immunome returns over 5 years
$1,000 invested in Immunome five years ago was worth $776.88 at the close on October 30, 2026, with dividends reinvested: an average return of -4.9% a year. The same $1,000 in the S&P 500 (SPY) became $1,760.
Total return by period
| Period | Total return | A year, on average | $1,000 became | S&P 500 (SPY) |
|---|---|---|---|---|
| 1 month | -15.3% | — | $846.58 | -0.9% |
| 3 months | -21.1% | — | $789.00 | +2.1% |
| Year to date | -15.2% | — | $847.77 | +11.7% |
| 1 year | +14.0% | — | $1,140 | +12.4% |
| 3 years | +106.9% | +27.4% | $2,069 | +88.5% |
| 5 years | -22.3% | -4.9% | $776.88 | +76.0% |
Immunome return by calendar year
| Year | IMNM | S&P 500 (SPY) | Difference |
|---|---|---|---|
| 2026 to date | -15.2% | +11.7% | -26.9% |
| 2025 | +102.3% | +17.7% | +84.5% |
| 2024 | -0.7% | +24.9% | -25.6% |
| 2023 | +384.2% | +26.2% | +358.0% |
| 2022 | -82.9% | -18.2% | -64.8% |
| 2021 | +33.9% | +28.7% | +5.1% |
Past returns do not predict future returns. Returns are computed from our daily closes, adjusted for splits and with dividends reinvested on their ex-dates; taxes and trading costs are left out.
See also: IMNM financials
No forecast, no recommendation. This page describes Immunome Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.